<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Oppenheimer sees stronger growth at Boston Scientific â€” Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Oppenheimer sees stronger growth at Boston Scientific</h2>
    <div class="badge">2025-09-08T16:50:57+00:00</div>
    <ul>
      <li>They forecast annual growth of 11-13%, which was well above the broader medtech sector.</li>
<li>Boston Scientific was upgraded from Perform with a $125 price target.</li>
<li>Coverage of Tandem Diabetes was also assumed with an Outperform rating, though its target price was cut to $22 from $44.</li>
<li>Insulet was reiterated at Outperform and its target price raised to $365 from $324 following second-quarter results.</li>
<li>It could weigh on margins despite strong sales potential.</li>
<li>Investing.com -- Oppenheimer analysts shifted ratings on U.S.</li>
<li>Oppenheimer cited second-quarter performance and valuation adjustments.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Oppenheimer%20sees%20stronger%20growth%20at%20Boston%20Scientific%0A%E2%80%A2%20They%20forecast%20annual%20growth%20of%2011-13%25%2C%20which%20was%20well%20above%20the%20broader%20medtech%20sector.%0A%E2%80%A2%20Boston%20Scientific%20was%20upgraded%20from%20Perform%20with%20a%20%24125%20price%20target.%0A%E2%80%A2%20Coverage%20of%20Tandem%20Diabetes%20was%20also%20assumed%20with%20an%20Outperform%20rating%2C%20though%20its%20target%20price%20was%20cut%20to%20%2422%20from%20%2444.%0A%E2%80%A2%20Insulet%20was%20reiterated%20at%20Outperform%20and%20its%20target%20price%20raised%20to%20%24365%20from%20%24324%20following%20second-quarter%20results.%0A%E2%80%A2%20It%20could%20weigh%20on%20margins%20despite%20strong%20sales%20potential.%0A%E2%80%A2%20Investing.com%20--%20Oppenheimer%20analysts%20shifted%20ratings%20on%20U.S.%0A%E2%80%A2%20Oppenheimer%20cited%20second-quarter%20performance%20and%20valuation%20adjustments.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Foppenheimer-sees-stronger-growth-at-boston-scientific%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/oppenheimer-sees-stronger-growth-boston-165057851.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>